College News

Pregnant women with obesity face an increased risk of complications, including the need for a cesarean section, which carries its own set of risks. A University of Oklahoma physician-researcher recently earned a $3.1 million National Institutes of Health grant to lead a multicenter national clinical trial studying whether antibiotics given at the beginning of labor induction result in a decrease in C-sections. The trial is thought to be the first large-scale study of its kind in the United States.

Ian F. Dunn, M.D., executive dean of the University of Oklahoma College of Medicine and professor of neurosurgery, has been named a new member of the American Academy of Neurological Surgery, a premier neurosurgical professional society in North America.

The University of Oklahoma College of Medicine is proud to announce that Jason Wagner, MD, Professor and Vice Chair of the Department of Radiological Sciences, has been elected to a five-year term on the executive board of the Society of Radiologists in Ultrasound. Wagner will begin his term as secretary in 2025, serving as treasurer in 2026, president-elect in 2027, and president of society in 2028. His term will conclude as immediate past-president in 2029.

Recruitment is underway for a University of Oklahoma College of Medicine study that seeks to better understand the factors driving Type 2 diabetes in youth, with the aim of determining who is at highest risk for developing the disease. OU is part of a nationwide consortium funded by the National Institutes of Health to address the dramatic rise of youth diagnosed with Type 2 diabetes over the past two decades, a trend that is expected to continue.

Patients discharged from the hospital after treatment for a major infection often continue receiving antibiotics through an IV line at home. However, medication adherence can be challenging because of a variety of barriers, and patients often find themselves readmitted to the hospital with infection-related complications. IV Ensure, an innovative remote therapeutic monitoring device being studied in a University of Oklahoma clinical trial, reduced the odds of infection-related hospital readmission by 76% at 30 days after hospital discharge and by 68% up to 90 days after discharge.